In the second of a tw0-part interview, LeafCann chief executive Elisabetta Faenza tells Cannabiz of the company’s future plans – including the development of a $350m facility – and reveals how it will make medicinal cannabis more affordable for patients.

For those becoming restless over the progress of Australia’s medicinal cannabis industry, a relatively recent history lesson may be in order.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

It should, argues Elisabetta Faenza, provide a little perspective on the progress made in the four years since legalisation.

The history lesson dates to the early decades of the 20th century when antibiotics were truly making their mark in the world of science and medicine.

LeafCann chief executive Elisabetta Faenza

“When we think about our sector and that stage of maturity we have reached, it is akin to the early days of antibiotics in the lead up to World War II,” the LeafCann chief executive says.

“Antibiotics went from a traditional therapy used to treat infections before we even knew about bacteria to a highly developed range of mass-produced medicine available throughout the world.

“What we know about antibiotics now in the many forms they are delivered, including dosing control, quality and information for doctors and pharmacists, has changed dramatically over the last 100 years.”

The first modern antibiotic was discovered in 1909 to treat syphilis, she adds. But it took another 30 years for the name antibiotic to enter the medical lexicon.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...